Real-World COPD study tracks benefits of switching to triple inhaler
NCT ID NCT05915182
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 212 adults with moderate to severe COPD in Greece who were prescribed a triple-combination inhaler (Trixeo Aerosphere). Researchers tracked why patients switched from dual therapy and how their symptoms and quality of life changed over 52 weeks. The goal was to see if the switch helps in everyday medical practice, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Budesonide, Glycopyrronium bromide, Formoterol fumarate (Trixeo Aerosphere inhaler)
What this could lead to
If successful, this study could show that switching to triple therapy improves daily life for COPD patients in real-world settings, helping doctors make better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (212 people) and limited to Greece, so findings may not apply everywhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Alexandroupoli, 68100, Greece
-
Research Site
Athens, 11521, Greece
-
Research Site
Athens, 11527, Greece
-
Research Site
Athens, 12462, Greece
-
Research Site
Athens, 17562, Greece
-
Research Site
Corfu, 49100, Greece
-
Research Site
Crete, 71409, Greece
-
Research Site
Crete, 71500, Greece
-
Research Site
Crete, 73300, Greece
-
Research Site
Ioannina, 45500, Greece
-
Research Site
Larissa, 41110, Greece
-
Research Site
Pátrai, 26332, Greece
-
Research Site
Pátrai, 26504, Greece
-
Research Site
Thessaloniki, 56429, Greece
-
Research Site
Thessaloniki, 57010, Greece